Large drugmakers spent millions protecting their CEOs last year amid 'heightened risk environment'
With fears increased in the healthcare industry that top executives could be targets of violence, some pharma companies have been beefing up security protocols for their CEOs. As U.S. drugmakers have released their proxy statements over the last few weeks, several reported large expenditures to protect their top execs.
With fears increased in the healthcare industry that top executives could be targets of violence, some pharma companies have been beefing up security protocols for their CEOs. As U.S. drugmakers have released their proxy statements over the last few weeks, several reported large expenditures to protect their top execs.
